Back to Jobs
Xenon Pharmaceuticals
Marketing & Sales 2h ago

Director, Strategic Engagements, Northeast

Xenon Pharmaceutical
United StatesUnited States
Full-time
Not Disclosed
Senior-Level
VT

Does Xenon Pharmaceutical sponsor H-1B visas?

Check real filing data, salaries & approval rates on VisaTalentUSA

View Data →

Job Description

Key Skills Required

Master these to land this role

Sales RepresentativeMedical AffairsMarket AccessCross-functional CollaborationKey Account Management

Want to know if you're a match for this job?

Calculate My Match Score

Who We Are:

Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.

What We Do:

We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy, depression, and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we submitted a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 and XEN1720 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are being developed for pain.

About the Role:

We are seeking a Director, Strategic Engagements, Northeast to join our team. The individual will be an integral member of the Commercial team and will support commercially focused HCP engagement activities for Azetukalner.

The key primary responsibility is to support key US Commercial Strategic market development strategies for the epilepsy launch. Individuals should be exceptional business leaders with 10+ years of epilepsy experience who will work regionally to maintain:

  • KOL Engagement
  • Uncover key market impact drivers
  • Support regional business planning across matrix colleagues

This role ensures close working relationships with cross-functional partners in a compliant manner.

This position requires close collaboration with the Commercial team, Medical Affairs, and other key business partners to elevate corporate brand awareness and advocacy. This role requires the ability to thrive in a dynamic and ambiguous environment. The position will require greater than 50% travel (up to 75%) to field-based educational events (many occurring on weekends). This includes internal meetings, advisory boards, medical meetings, and congresses.

This position reports to the Senior Director, Customer Engagement, and will be fully remote.

RESPONSIBILITIES:

  • Identify, cultivate, and maintain long-term relationships with national and regional epilepsy KOLs, advisors, and other influential stakeholders.
  • Own commercial KOL influence mapping, including stakeholder profiling, engagement strategies, and communication plans that inform customer prioritization and commercial planning.
  • Monitor and synthesize stakeholder insights, treatment trends, unmet needs, and competitive dynamics, translating findings into actionable recommendations that inform commercial strategy, launch readiness, and regional business decisions.
  • Serve as a strategic advisor to Commercial leadership by providing market intelligence, stakeholder perspectives, and recommendations that shape launch planning, customer engagement strategies, and business priorities.
  • Support launch readiness initiatives by identifying and engaging key stakeholders who influence awareness, perception, advocacy, treatment positioning, and early adoption of Azetukalner within assigned regions.
  • Lead cross-functional coordination across Commercial, Medical Affairs, Market Access, Advocacy, and other matrix partners to ensure aligned customer engagement strategies and execution.
  • Drive coordinated account planning by integrating stakeholder insights and partnering across matrix teams to develop and execute aligned engagement plans for priority customers and accounts.
  • Identify emerging market opportunities, barriers to adoption, and customer needs, and recommend actions that strengthen launch preparedness and commercial execution.
  • Attend and lead strategic engagement activities at national and regional congresses, professional meetings, and key industry events, including stakeholder mapping, partner engagement, and field education support.
  • Collaborate with Marketing, Analytics, Medical Affairs, and other cross-functional partners to refine disease-state education, brand strategy, customer engagement approaches, and market development initiatives.
  • Identify and develop strategic partnerships with professional societies, advocacy organizations, and other external stakeholders to advance disease awareness, education, and advocacy efforts.
  • Facilitate and coordinate high-impact engagements between Xenon senior leadership and national and regional KOLs.
  • Formalize meetings (live, virtual, Congress) with senior leadership and National and Regional KOLs.
  • Develop and propose short- and long-term objectives for the function in accordance with overall Company strategies and plans.
  • Plan and manage budget proposals and approved budgets in accordance with the Company’s strategic and operating plans and Finance policies.
  • Recruit, lead, direct, develop, coach, and evaluate direct reports, if any, in accordance with the Company’s Human Resource policies and practices.
  • Act in accordance with Company policies, including the Code of Business Conduct and Ethics, and ensure policies are understood and followed by direct reports, if any.
  • Travel is 50-75%.
  • Region covers: MA, NY, PA, NJ, CT, RI, VT, NH, ME.
  • International travel may be required.
  • Other duties as assigned.

QUALIFICATIONS:

  • A minimum of a BA/BS Degree in a related field is required; MBA, PharmD, PhD, or other related graduate degree preferred.
  • A minimum of 10 years of experience in Epilepsy marketing, medical, key account management, sales, or sales leadership, ideally engaging with KOLs/Influential HCPs and professional healthcare organizations.
  • Deep understanding and experience working cross-functionally with various key internal and external stakeholders with a strong ability to innovate, collaborate, and deliver results with desired outcomes.
  • Demonstrated understanding of key industry trends and ability to develop strategies to stay ahead of the competition and maximize patient outcomes.
  • Demonstrated ability to build and manage relevant and lasting customer relationships with a strong focus on patient impact and outstanding customer centricity.
  • Excellent interpersonal, verbal, and written communication skills.
  • Able to work independently under tight timelines and be willing to contribute significantly to day-to-day operations as needed.

How would you rate this job post?

See what other professionals think about this role.

banner
logo

Xenon Pharmaceuticals

View Company Profile

Xenon Pharmaceuticals Inc. (operating under xenon-pharma.com) is the premier, enterprise-grade neuroscience biotechnology powerhouse, ion channel science pioneer, and therapeutic development innovation leader engineered to act as the definitive, high-velocity discovery and clinical-stage engine for transformative treatments across epilepsy, depression, and severe neurological conditions. Founded to bridge the gap between complex human genetic insights and the rigorous development of selective molecular chemistries, the company completely eliminates the severe systemic friction of modern CNS drug development—where traditional trial-and-error chemical synthesis fails to navigate the blood-brain barrier effectively, ignores critical genetic markers for patient stratification, and suffers from low signal-to-noise ratios in ion channel modulation—by deploying a sophisticated, biology-first computational and laboratory matrix. Moving far beyond traditional, passive small-molecule discovery pipelines, Xenon natively unifies deep, multi-decade proprietary human genetics databases, high-throughput ion channel assay screening platforms, and precision chemistry optimization frameworks into a single high-availability clinical development workspace. Its primary research engine centers on its potent, selective ion channel targeting capabilities, currently anchored by its late-stage investigational candidate, azetukalner, which serves as a flagship asset in the treatment of challenging neurological and psychiatric indications. Operating as a public-market titan (NASDAQ: XENE) with deep institutional backing, the corporation maintains a robust pipeline of high-potential neurological therapies while consistently pioneering advancements in peripheral and central nervous system signaling pathways. Under the hood, its technology core utilizes advanced predictive pharmacokinetic modeling, automated high-throughput electrophysiology, and rigorous clinical trial data orchestration designed to accelerate drug candidate translation from the bench to pivotal phase 3 study completion without losing structural regulatory compliance or scientific velocity. What sets Xenon apart is its uncompromising dedication to replacing fragile, historically stagnant neuroscience development models with absolute scientific predictability, genomic-driven patient stratification, and elite-tier clinical trial execution; by bridging the gap between performance-intensive structural biology and the immediate, critical needs of patients suffering from debilitating neurological conditions, the enterprise remains a definitive cornerstone of modern algorithmic biotechnology and global nervous system therapeutic transformation.

Safety First

  • Never pay for a job application.
  • Do not share sensitive bank info.
  • Verify the client before starting work.
Learn More